Lilly Pill Cuts Sleep Apnea by 44% in Late Trial
Lilly Pill Cuts Sleep Apnea by 44% in Late Trial
Lilly Pill Cuts Sleep Apnea by 44% in Late Trial
Key points
اہم نکات
मुख्य बातें
- Eli Lilly said its daily obesity pill Foundayo sharply reduced sleep apnea in two late-stage trials, cutting breathing interruptions by 43.8 percent in patients not using breathing machines, compared with 6.3 percent on a placebo.
- In the 52-week studies of 712 adults with obesity, nearly a third of patients not using machines saw their condition go into remission or improve to mild.
- Lilly plans to ask US regulators by the end of the year to approve the pill for moderate-to-severe sleep apnea.
- Eli Lilly said its daily obesity pill Foundayo sharply reduced sleep apnea in two late-stage trials, cutting breathing interruptions by 43.8 percent in patients not using breathing machines, compared with 6.3 percent on a placebo.
- In the 52-week studies of 712 adults with obesity, nearly a third of patients not using machines saw their condition go into remission or improve to mild.
- Lilly plans to ask US regulators by the end of the year to approve the pill for moderate-to-severe sleep apnea.
- Eli Lilly said its daily obesity pill Foundayo sharply reduced sleep apnea in two late-stage trials, cutting breathing interruptions by 43.8 percent in patients not using breathing machines, compared with 6.3 percent on a placebo.
- In the 52-week studies of 712 adults with obesity, nearly a third of patients not using machines saw their condition go into remission or improve to mild.
- Lilly plans to ask US regulators by the end of the year to approve the pill for moderate-to-severe sleep apnea.
Eli Lilly said its daily obesity pill Foundayo sharply reduced sleep apnea in two late-stage trials, cutting breathing interruptions by 43.8 percent in patients not using breathing machines, compared with 6.3 percent on a placebo. In the 52-week studies of 712 adults with obesity, nearly a third of patients not using machines saw their condition go into remission or improve to mild. Lilly plans to ask US regulators by the end of the year to approve the pill for moderate-to-severe sleep apnea.
Eli Lilly said its daily obesity pill Foundayo sharply reduced sleep apnea in two late-stage trials, cutting breathing interruptions by 43.8 percent in patients not using breathing machines, compared with 6.3 percent on a placebo. In the 52-week studies of 712 adults with obesity, nearly a third of patients not using machines saw their condition go into remission or improve to mild. Lilly plans to ask US regulators by the end of the year to approve the pill for moderate-to-severe sleep apnea.
Eli Lilly said its daily obesity pill Foundayo sharply reduced sleep apnea in two late-stage trials, cutting breathing interruptions by 43.8 percent in patients not using breathing machines, compared with 6.3 percent on a placebo. In the 52-week studies of 712 adults with obesity, nearly a third of patients not using machines saw their condition go into remission or improve to mild. Lilly plans to ask US regulators by the end of the year to approve the pill for moderate-to-severe sleep apnea.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।